

Alexander Drive, Building. 4401,
Room 102, P.O. Box 12233, EC-32,
Research Triangle Park, NC 27709
Phone: (919) 541-3455, Fax: (919)
316-4511, shelby@niehs.nih.gov.

Dated: August 2, 2001.

Samuel H. Wilson,

*Deputy Director, National Institute of
Environmental Health Sciences.*

[FR Doc. 01-20190 Filed 8-10-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health,
Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below
are owned by agencies of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.

ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by
contacting Susan S. Rucker, J.D., at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/
496-7056 ext. 245; fax: 301/402-0220;
e-mail: ruckers@od.nih.gov. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.

Modified Leptin

YP Loh, NX Cawley (both of NICHD)
Serial No. 60/290,722 filed 14 May 2001

This invention described and claimed
in this patent application provides for
an improved method for producing
human leptin *in vitro* or in *in vivo*. In
particular, the patent application
describes compositions and methods
which are based on a modified form of
human leptin where the regulated
secretory pathway (RSP) sorting signal
has been modified to provide for the
constitutive secretion of leptin via the
nonregulated secretory pathway (NRSP)
in a mammalian cell. This invention can
be applied to a non-invasive method of

gene therapy to achieve sustained
delivery of this therapeutic protein.

Modified Growth Hormone

YP Loh, NX Cawley (both of NICHD), BJ
Baum (NIDCR), and CR Snell
Serial No. 60/290,836 filed 14 May 2001

This invention described and claimed
in this patent application provides for
an improved method for producing
human growth hormone *in vitro* or in *in vivo*. In particular, the patent
application describes compositions and
methods which are based on a modified
form of human growth hormone where
the regulated secretory pathway (RSP)
sorting signal has been modified to
provide for the constitutive secretion of
human growth hormone via the
nonregulated secretory pathway (NRSP)
in a mammalian cell. This invention can
be applied to a non-invasive method of
gene therapy to achieve sustained
delivery of this therapeutic protein.

Dated: August 6, 2001.

Jack Spiegel,

*Director, Division of Technology,
Development and Transfer, Office of
Technology Transfer, National Institutes of
Health.*

[FR Doc. 01-20193 Filed 8-10-01; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Research Resources; Notice of Meetings

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of meetings of the
National Advisory Research Resources
Council.

The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.

The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which

would constitute a clearly unwarranted
invasion of personal privacy.

Name of Committee: National Advisory
Research Resources Council Executive
Subcommittee.

Date: September 13, 2001.

Open: 8:00 am to 9:00 am.

Agenda: To discuss policy issues.

Place: National Center for Research
Resources, National Institutes of Health,
Conference Room 3B13, Building 31,
Bethesda, MD 20892.

Contact Person: Louise E. Ramm, PhD,
Deputy Director, National Center for
Research Resources, National Institutes of
Health, Building 31, Room 3B11, Bethesda,
MD 20892, 301-496-6023.

Name of Committee: National Advisory
Research Resources Council.

Date: September 13, 2001.

Open: 9:15 am to 3:00 pm.

Agenda: Report of Center Director and
other issues.

Place: National Institutes of Health, 9000
Rockville Pike, Conference Room 10,
Building 31C, Bethesda, MD 20892.

Closed: 3:00 pm to Adjournment.

Agenda: To review and evaluate grant
applications.

Place: National Institutes of Health, 9000
Rockville Pike, Conference Room 10,
Building 31C, Bethesda, MD 20892.

Contact Person: Louise E. Ramm, PhD,
Deputy Director, National Center for
Research Resources, National Institutes of
Health, Building 31, Room 3B11, Bethesda,
MD 20892, 301-496-6023.

Information is also available on the
Institute's/Center's home page:
www.ncrr.nih.gov/newspub/minutes.htm,
where an agenda and any additional
information for the meeting will be posted
when available.

(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine,
93.306; 93.333, Clinical Research, 93.333;
93.371, Biomedical Technology; 93.389,
Research Infrastructure, National Institutes of
Health, HHS)

Dated: August 6, 2001.

LaVerne Y. Stringfield,

*Director, Office of Federal Advisory
Committee Policy.*

[FR Doc. 01-20207 Filed 8-10-01; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Child Health and Human Development; Notice of Closed Meeting

Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.

The meeting will be closed to the
public in accordance with the